COVID-19 convalescent plasma therapy decreases inflammatory cytokines: a randomized controlled trial

By sjmartinez • November 28, 2023

Habtehyimer F, Zhu X, Redd AD, Gebo KA, Abraham AG, Patel EU, Laeyendecker O, Gniadek TJ, Fernandez RE, Baker OR, Ram M, Cachay ER, Currier JS, Fukuta Y, Gerber JM, Heath SL, Meisenberg B, Huaman MA, Levine AC, Shenoy A, Anjan S, Blair JE, Cruser D, Forthal DN, Hammitt LL, Kassaye S, Mosnaim GS, Patel B, Paxton JH, Raval JS, Sutcliffe CG, Abinante M, Oei KS, Cluzet V, Cordisco ME, Greenblatt B, Rausch W, Shade D, Gawad AL, Klein SL, Pekosz A, Shoham S, Casadevall A, Bloch EM, Hanley D, Tobian AAR, Sullivan DJ. COVID-19 convalescent plasma therapy decreases inflammatory cytokines: a randomized controlled trial. Microbiol Spectr. 2023 Nov 27:e0328623. doi: 10.1128/spectrum.03286-23. Epub ahead of print. PMID: 38009954.

Tags: chemokines, convalescent plasma, covid-19, COVID-19 serotherapy, Cytokines, Infectious Diseases, Publications, randomized trial, SARS-CoV-2

Editorial: Improving the delivery of pre-exposure prophylaxis (PrEP) to eliminate vertical HIV transmission

Njuguna I, Saidi F, Joseph Davey D, Chi BH, Pintye J. Editorial: Improving the delivery of pre-exposure prophylaxis (PrEP) to eliminate vertical HIV transmission. Front[...]

Efficacy of an oral lipid nanocrystal formulation of amphotericin B (MAT2203) in the neutropenic mouse model of pulmonary mucormycosis

Gu Y, Gebremariam T, Alkhazraji S, Youssef E, El-Gamal S, Matkovits T, Cobb J, Mannino R, Ibrahim AS. Efficacy of an oral lipid nanocrystal formulation[...]

A novel risk-adjusted metric to compare hospitals on their antibiotic-prescribing at hospital discharge

Livorsi DJ, Merchant JA, Cho H, Goetz MB, Alexander B, Beck B, Goto M. A novel risk-adjusted metric to compare hospitals on their antibiotic-prescribing at[...]